Summary
a2 Milk Company partnered with China State Farms Holdings Shanghai at the China International Import Expo (CIIE) on 10 November 2026 to launch three new infant formula products for the Chinese market: a2 Platinum ZhiChu Qirun, a2 Platinum ZhiChu Zhichun and an upgraded version of a2 Platinum Zi Bai Jin. The Zi Bai Jin upgrade was the focus of the launch. As a2's core global product line, the upgraded version had its global debut at CIIE and was released simultaneously in Australia/New Zealand and China.
Li Xiao, CEO of a2 Greater China, said the simultaneous release of the upgraded Zi Bai Jin in Australia/New Zealand and China marks an important step in the brand's development. The ZhiChu family now includes the new Qirun and Zhichun products, responding to different consumer priorities with a key nutrient combination matching maternal milk and an organic nutrition concept. The new products' milk source and production rely on a2's integrated nutrition manufacturing plant in Pokeno, North Island, New Zealand.
The plant is New Zealand's newest world-class infant formula factory built in nearly 20 years, with annual capacity of tens of millions of cans, using a wet process that turns fresh milk into powder in a single step. Financial results show that a2's full-year revenue for the 2026 financial year ended June reached NZ$1.975 billion, up 12.4 percent year on year. In a Chinese infant formula market that was flat overall, total infant formula revenue rose 4.7 percent year on year.
Cross-border infant formula business for China and other Asian regions achieved sales revenue of NZ$714.6 million, up 27.8 percent year on year, with a market share of 19.5 percent. Revenue from the family nutrition product series grew 59.9 percent. David Bortolussi, Managing Director and CEO of a2 Milk Company, said China remains an important part of a2's global development strategy.
Infant formula is one of its core categories for long-term development in China. The company will continue to enrich product choices around the changing needs of Chinese families and drive the brand's continued development in full-life-stage nutrition products.
Commentary
a2 Milk Company's launch of three new infant formula products at this year's CIIE, including the global simultaneous debut of the Zi Bai Jin series, underscores China's central role in its strategy. As an important player in New Zealand's dairy industry, a2 leverages the capacity and wet process of its Pokeno integrated plant to strengthen full-chain control from milk source to finished product, offering a reference for vertical supply chain integration among New Zealand SMEs. In FY2026, a2's China cross-border infant formula business grew 27.8 percent with a market share of 19.5 percent, while China's overall infant formula market was flat, showing that niche segments and channel innovation can still create growth.
For NZ SMEs, the 59.9 percent revenue growth in a2's family nutrition products suggests dairy companies should look to 'full lifecycle' positioning that extends from infant to adult and elderly nutrition, using New Zealand's clean milk source image to enter functional dairy. Meanwhile, a2's channel partnership with China State Farms is worth studying; small and medium brands can lower market entry barriers by partnering with local Chinese distributors. China's infant formula market has entered stock competition, but cross-border channels and high-end niches still offer room.
New Zealand companies need to build barriers in differentiated areas such as organic, A2 protein and grass-fed to avoid price wars with local brands.
Keywords: a2 Milk Company, CIIE, new infant formula products, upgraded Zi Bai Jin, ZhiChu family, Pokeno plant, FY2026 results, cross-border infant formula business, family nutrition, China market
Photo by TheDigitalArtist on Pixabay
Source: Hithink RoyalFlush
Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.






